We further examined the proportion of immune cells in the TIME using flow cytometry analysis after tissue digestion (Supplementary Fig S6A, B) and found that human CD45+ CD14+ monocytes, CD45+ CD19+ B cells, CD45+ CD3+ T cells, and CD45+ CD56+ NK cells in NPC tumors were not affected by lenvatinib treatment (Fig. 7H). This evidence concerns the gene CD19 and nasopharyngeal carcinoma.